Company: OSRH
Filing Date: 2025-01-29
Form Type: S-4/A
Source: 0001213900-25-007923
Chunk: 416

Company: OSR Holdings, Inc.
Filing Date: 2025-01-29
Form: S-4/A
Chunk 416
---
     |    9 |     |       28 |     |         |
| Test    |     |       2 |     |    4 |     |        6 |     |   0.026 |     | Test    |     |      24 |     |    8 |     |       32 |     |   0.002 |
|         |     |         |     |      |     |       30 |     |         |     |         |     |         |     |      |     |       60 |     |         |

Note: S = Bone Fusion Success; F = Bone Fusion Failure; a = Continuous trabeculation formation; b = Evidence of bone remodeling; c = Absence of radiolucent areas The clinical trial results indicate that the success rate in the test group was significantly higher at 75%, compared to only 25% in the control group. Additionally, the failure rate in the control group was 71.4%, which was markedly higher than the 28.6% observed in the test group. These findings demonstrate that the test group, which received DRT -102, exhibited a substantially better outcome in terms of bone fusion compared to the control group. Overall, the data strongly suggest that DRT -102is more effective than the control treatment in promoting bone fusion. The chi -squaretest of the study demonstrates how the p -valuechanges with varying sample sizes in the clinical trial, comparing the control and test groups. Initially, with a smaller sample size of 15 patients, the p -valueis 0.132, indicating no statistically significant difference between the two groups. However, as the sample size increases to 23 patients, the p -valuedrops to 0.039, suggesting a statistically significant difference favoring the test group. With a moderate sample size of 30 patients, the p -valuefurther decreases to 0.026, indicating stronger statistical evidence of the difference in success rates between the control and test groups. Finally, in the largest sample size of 60 patients, the p -valuereaches 0.002, demonstrating a statistically significant difference. Throughout the analysis, the test group outperformed the control group in success rates. Development plans for DRT-101 and DRT-102 Based on preliminary tests of DRT -101and DRT -102, Darnatein intends to expand the potential application of DRT -101to other cartilage regeneration targets, including spinal cartilage